SKYSTAR BIO-PHARMACEUTICAL CO Financing Receivable, after Allowance for Credit Loss, Current
SKYSTAR BIO-PHARMACEUTICAL CO had Financing Receivable, after Allowance for Credit Loss, Current of CNY 6.45 million as of 2014-09-30, per its 10-Q filed 2014-11-14.
Discontinued › Balance Sheet › Assets › Assets, Current › Accounts and Financing Receivable, after Allowance for Credit Loss, Current
us-gaap:NotesAndLoansReceivableNetCurrent · last filed 2014-11-14
- 2014-09-30: Financing Receivable, after Allowance for Credit Loss, Current 6.45M CNY.
- 2014-06-30: Financing Receivable, after Allowance for Credit Loss, Current 6.45M CNY.
- 2014-03-31: Financing Receivable, after Allowance for Credit Loss, Current 6.45M CNY.
- 2014-01-02: Financing Receivable, after Allowance for Credit Loss, Current 8.00M CNY.
CNY
| Period end | Financing Receivable, after Allowance for Credit Loss, Current |
|---|---|
| 2014-09-30 | 6.45M CNY 10-Q · filed 2014-11-14 |
| 2014-06-30 | 6.45M CNY 10-Q · filed 2014-08-14 |
| 2014-03-31 | 6.45M CNY 10-Q · filed 2014-05-15 |
| 2014-01-02 | 8.00M CNY 10-Q · filed 2014-11-14 |
USD
| Period end | Financing Receivable, after Allowance for Credit Loss, Current | Financing Receivable, after Allowance for Credit Loss, Current as first filed |
|---|---|---|
| 2014-09-30 | $1.05M 10-Q · filed 2014-11-14 | |
| 2014-06-30 | $1.05M 10-Q · filed 2014-08-14 | |
| 2014-03-31 | $1.05M 10-Q · filed 2014-05-15 | |
| 2014-01-02 | $1.30M 10-Q · filed 2014-11-14 | $1.30M 10-Q · filed 2014-05-15 |
| 2013-12-31 | $0.00 10-Q · filed 2014-05-15 | |
| 2013-09-30 | $0.00 10-Q · filed 2013-11-14 | |
| 2013-06-30 | $194.40K 10-Q · filed 2013-08-14 | |
| 2013-03-31 | $1.08M 10-Q · filed 2013-05-15 | |
| 2012-12-31 | $1.08M 10-K · filed 2014-03-31 | |
| 2012-09-30 | $2.11M 10-Q · filed 2012-11-14 | |
| 2012-06-30 | $2.91M 10-Q/A · filed 2012-09-13 | |
| 2012-03-31 | $981.70K 10-Q · filed 2012-05-15 | |
| 2011-12-31 | $964.09K 10-K · filed 2013-04-01 | |
| 2011-09-30 | $0.00 10-Q · filed 2011-11-14 | |
| 2011-06-30 | $2.11M 10-Q/A · filed 2011-09-21 | |
| 2010-12-31 | $8.04M 10-K · filed 2012-03-30 | |
| 2010-12-30 | $8.04M 10-Q · filed 2011-11-14 |